Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy ADT in High Risk Prostate Cancer with Initial Phase I NADIR Randomized Phase II Trial of Niraparib with Standard Combination Androgen Deprivation Therapy ADT and Radiotherapy in High Risk Prostate Cancer with Initial Phase I
A Phase III, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA IT PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Phase III Study, CONTACT-02: A Phase III, Randomized, Open-Label, Controlled Study of Cabozantinib XL 184 in Combination with Atezolizumab vs Second Novel Hormonal Therapy NHT in Subjects with Metastatic Castration-Resistant Prostate Cancer
HoLEP prior to Radiation Therapy for Patients with LUTS/Retention and Concurrent Prostate Cancer
Study Type: Supportive Care
Phase: N/A
NCTID: NCT03802851
Principal Investigator:
Bristol Whiles
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium 177Lu vipivotide tetraxetan AAA617 versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen PSMA positive Oligometastatic Prostate Cancer OMPC
Study Type: Treatment
Phase: III
NCTID: NCT05939414
Principal Investigator:
Xinglei Shen
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer COMPPARE
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Study Type: Treatment
Phase: III
NCTID: NCT05838716
Principal Investigator:
Elizabeth Wulff-Burchfield
Pilot Trial of Ultra-Hypofractionated Radiation in Early Prostate Cancer
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT03486821
Principal Investigator:
Xinglei Shen